Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celera forms pact with Bristol-Myers Squibb:

This article was originally published in Clinica

Executive Summary

Celera Diagnostics has linked up with Bristol-Myers Squibb (BMS) to study genes that may be useful for diagnosing and treating cardiovascular disease and diabetes. Under the terms of an agreement between the two firms, BMS will receive exclusive rights to develop and market drugs for cardiovascular disease and diabetes based on therapeutic targets identified by the studies conducted by Celera. Celera will retain exclusive rights to develop and market diagnostic products. Alameda, California-based Celera recently formed deals with Laboratory Corporation of America and Quest Diagnostics (see Clinica 1028, p 22).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT068490

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel